
Astrazeneca Reportedly Nears Drug Pricing Deal With President Trump
AstraZeneca PLC (AZN) is reportedly set to unveil a deal with U.S. President Donald Trump about reducing drug prices.
According to a Bloomberg News report, citing sources familiar with the matter, the agreement would mark the second such partnership by a pharmaceutical company to help progress one of Trump's central healthcare initiatives.
The report noted that the details about the pact weren't immediately clear. The agreement is part of the Trump administration's efforts to lower drug prices in the U.S. and to ensure that wealthy nations contribute more significantly to the cost of developing breakthrough medical innovations.
Get updates to this developing story directly on Stocktwits.
For updates and corrections, email newsroom[at]stocktwits[dot]com.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Crypto Market Update: Pepeto Advances Presale With Staking Rewards And Live Exchange Demo
- Kucoin Appeals FINTRAC Decision, Reaffirms Commitment To Compliance
- Cregis And Sumsub Host Web3 Compliance And Trust Summit In Singapore
- Chartis Research And Metrika Release Comprehensive Framework For Managing Digital Asset Risk
- Nodepay Launches Crypto's Largest Prediction Intelligence Platform
- Schoenherr Opens London Liaison Office As Gateway To Central Eastern Europe
Comments
No comment